US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.12 — a beat of 0.0%.
Analysts rate OmniAb Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $8.33.
CONFIDENT OmniAb reported strong year-to-date revenue growth, raised 2026 revenue and cash guidance, expanded partnerships, and highlighted momentum in xPloration and clinical programs. Q3 FY26 OmniAb reported 111 active partners, including 9 of the 10 largest pharmaceutical companies, and batoclimab received Chinese approval after quarter-end. Analysts focused on revenue mix, milestone timing, xPloration commercialization, royalty potential, and investment needs. Management emphasized diversified service drivers, substantial potential milestones, and disciplined spending. 2026-10-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| Whitefort Capital Management, LP. | 7.05% |
| BlackRock Inc | 6.12% |
| Nomura Holdings Inc | 3.46% |
| Cadian Capital Management LP | 2.90% |
| Vanguard Capital Management, LLC | 2.65% |
| Geode Capital Management, LLC | 1.98% |
| Rice Hall James & Associates, LLC | 1.80% |
| Private Management Group Inc | 1.61% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • OmniAb reported third-quarter 2026 revenue of $3.993 million, up from $2.239 million in the third quarter of 2025. • Nine-month 2 | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $4.0 million, up from $2.2 million in the prior-year period. • Nine-month 2026 revenue was $31.8 m | 2026-10-30 |
| Quarterly report · Q2 2026 OMNIAB, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Total Revenue (6 months ended June 30, 2026): $27.8 million, up 246% vs. $8.1 million | 2026-08-06 |
| Results announced · Q3 2026 OMNIAB, INC. – Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 Revenue: $13.4 million vs. $3.9 million in Q2 2025 (244% increase) - L | 2026-08-06 |
| Board / officer change · Q3 2026 OMNIAB, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • New Chief Operating Officer appointed: Amechi Nwachuku appointed as COO effective Ju | 2026-07-13 |
| Shareholder vote results · Q2 2026 OMNIAB, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 17, 2026 • Company trades on Nasdaq Global Market under tick | 2026-06-18 |
| Quarterly report · Q1 2026 OMNIAB, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $29,046 thousand (March 31, 2026) vs. $25,524 thousand (December 3 | 2026-05-07 |
| Results announced · Q2 2026 OMNIAB Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q1 2026 Revenue: $14.4 million vs. $4.2 million in Q1 2025 (243% increase), primarily fr | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for OmniAb Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.